Core Insights - Rezolute, Inc. experienced a significant decline in share price following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, which is aimed at treating congenital hyperinsulinism [1] - The clinical trial did not meet its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [1] Market Reaction - During intraday trading, Rezolute's shares plummeted from approximately $10.94 to an intraday low of around $0.90, reflecting an approximate 85–90% drop as trading was halted under Nasdaq's volatility controls [2]

Economic Overview - The U.S. economy presents a mixed picture with consumer activity remaining intact but shifting towards necessities rather than discretionary spending [2] - Businesses are operating under tighter margins and selective demand, creating a functional yet vulnerable economy [2] Market Sentiment - Investors are becoming more cautious as expectations for 2026 are tempered due to slower economic momentum and rising uncertainty around corporate earnings [1][3] - The market may experience increased volatility as growth becomes less predictable and earnings visibility narrows [3] Defensive Stocks - Defensive stocks are expected to perform better during uncertain periods as they cater to everyday needs, providing more predictable revenues compared to cyclical businesses [4] - These stocks can help reduce portfolio volatility while still allowing for long-term market participation [5] Company Analysis: Turning Point Brands, Inc. (TPB) - TPB has seen a 40% increase in share price over the past year, benefiting from stable consumer demand in habitual consumption categories [6] - The company is focused on maintaining brand strength while evolving its portfolio to align with consumer preferences, including expanding into modern oral nicotine products [7] - The Zacks Consensus Estimate for TPB's EPS suggests growth of 50.6% for the current fiscal year and 7.1% for the next [8] Company Analysis: Johnson & Johnson (JNJ) - JNJ benefits from steady non-discretionary healthcare demand and a diversified portfolio in pharmaceuticals and medical technologies [11] - The company emphasizes disciplined innovation, advancing its pharmaceutical pipeline and enhancing its medical technology offerings [12] - The Zacks Consensus Estimate for JNJ's EPS indicates growth of 8.9% for the current fiscal year and nearly 5.7% for the next [13] Company Analysis: NextEra Energy, Inc. (NEE) - NEE has risen 12.1% in the past year, providing essential electricity services that support predictable operations and earnings visibility [14] - The company is positioned to benefit from long-term energy infrastructure demand driven by population growth and electrification trends [15] - The Zacks Consensus Estimate for NEE's EPS suggests growth of 7.6% for the current fiscal year and 7.8% for the next [16] Conclusion - As uncertainty increases approaching 2026, investors may prefer companies like TPB, JNJ, and NEE that offer stability through essential products and services while continuing to invest in growth initiatives [17]

The publication of this announcement is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any lo ...

CSPC Innovation Pharmaceutical Co., Ltd. 石藥創新製藥股份有限公司 The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (the "Company") (A joint stock company incorporated in the People's Republic of China with l ...

I'm Susan Jabinsky, co-host of the Morning Filter podcast. Today, we're looking at some top value stocks to buy and hold for 2026. These stocks have a few things in common.For starters, they land on the value side of the Morning Star style box. They also appear on Morning Star's best companies to own list. These companies have carved out wide economic moes, have predictable cash flows, and are managed by teams with a history of making smart capital allocation decisions.And best of all, these stocks all look ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Guangzhou Novaken Pharm Co., Ltd. 廣州新濟醫藥股份有限公司 (the "Company") (A joint stock company established in the People's R ...

Shares of 60 Degrees Pharmaceuticals Inc. (SXTP) have been struggling lately and have lost 19.7% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analys ...

记者丨黎雨桐 编辑丨金珊 北京时间23日晚间，美股小幅低开，截至23时左右，道琼斯指数跌0.03%，标普500指数跌0.02%，纳斯 达克综合指数跌0.13%。 美国科技七巨头普涨，亚马逊涨超1%。费城半导体指数跌0.62%，英伟达微涨0.34%，英特尔、超威半 导体等多股下跌。 诺和诺德大涨9.5%，消息面上，诺和诺德的重磅GLP-1类药物司美格鲁肽口服版减重药正式获得美国 FDA批准。公司表示，该药物将于明年1月初在美国上市。司美格鲁肽也成为全球范围内获得批准的首 款用于减重的GLP-1类药物，此前全球都没有用于减重的GLP-1口服片剂获批。 纳斯达克中国金龙指数跌1.2%，热门中概股多数承压，小鹏汽车跌超3.7%，名创优品、蔚来、理想、B 站、金山云均跌超2%。 | < w | 纳斯达克中国金龙指数(HXC) 7590.16 -93.10 -1.21% | | | | Q | | --- | --- | --- | --- | --- | --- | | 资料 | 资讯 成分 相关基金 | | | 月度收益 | | | 小鹏汽车 XPEV.N | | 19.275 | -3.72% | | -0.37 ...

I was losing hope regarding the oral semaglutide (aka Wegovy pill) gaining FDA approval, but the positive outcome came right before Christmas. I personally think this is the turning point for Novo Nordisk A/S (Hi there, welcome to my profile. My name is Eugenio Catone, I live in Italy and I am 27 years old.In 2023 I graduated in Business Administration and I completed CFA level 1 in 2024. I am currently a Popular Investor on the investing platform eToro, you can see there my public portfolio. My interest in ...

Core Viewpoint - The oral semaglutide (Wegovy pill) has gained FDA approval, marking a significant turning point for Novo Nordisk A/S [1] Group 1: FDA Approval Impact - The approval of the oral semaglutide is seen as a pivotal moment for Novo Nordisk, potentially enhancing its market position [1] Group 2: Company Background - Novo Nordisk is recognized for its innovative approaches in the pharmaceutical industry, particularly in diabetes and obesity treatments [1]